Loading...
Please wait, while we are loading the content...
Similar Documents
BC-Monitor: Towards a Routinely Accessible Circulating Tumor DNA-Based Tool for Real-Time Monitoring Breast Cancer Progression and Treatment Effectiveness
| Content Provider | MDPI |
|---|---|
| Author | Lajos, Pintér Bernadett, Csányi Eszter, Sági-Zsigmond Farkas, Sükösd Orsolya, Oláh-Németh Al, íz Nikolényi Gabriella, Uhercsák Roz, ália Tóth Zsuzsanna, Kahán Pólya, Sára Sántha, Dóra Szilágyi, Éva Priskin, Katalin Jaksa, Gábor Enyedi, Márton Kelemen, Gyöngyi Dobi, Ágnes Valicsek, Erzsébet Tordai, László Haracska, Lajos |
| Copyright Year | 2021 |
| Description | Circulating tumor DNA (ctDNA) is increasingly employed in the screening, follow-up, and monitoring of the continuously evolving tumor; however, most ctDNA assays validated for clinical use cannot maintain the right balance between sensitivity, coverage, sample requirements, time, and cost. Here, we report our BC-monitor, a simple, well-balanced ctDNA diagnostic approach using a gene panel significant in breast cancer and an optimized multiplex PCR-based NGS protocol capable of identifying allele variant frequencies below 1% in cell-free plasma DNA. We monitored a cohort of 45 breast cancer patients prospectively enrolled into our study receiving neoadjuvant chemotherapy or endocrine therapy or palliative therapy for metastatic diseases. Their tumor mutation status was examined in the archived tumor samples and plasma samples collected before and continuously during therapy. Traceable mutations of the used 38-plex NGS assay were found in approximately two-thirds of the patients. Importantly, we detected new pathogenic variants in follow-up plasma samples that were not detected in the primary tumor and baseline plasma samples. We proved that the BC-monitor can pre-indicate disease progression four–six months earlier than conventional methods. Our study highlights the need for well-designed ctDNA monitoring during treatment and follow-up, integrated into a real-time treatment assessment, which could provide information on the active tumor DNA released into the blood. |
| Starting Page | 3489 |
| e-ISSN | 20726694 |
| DOI | 10.3390/cancers13143489 |
| Journal | Cancers |
| Issue Number | 14 |
| Volume Number | 13 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-07-12 |
| Access Restriction | Open |
| Subject Keyword | Cancers Oncology Ctdna Treatment Response Next-generation Sequencing Liquid Biopsy Breast Cancer |
| Content Type | Text |
| Resource Type | Article |
